Investors

Cadrenal Therapeutics Announces Formation of Scientific Advisory Board PONTE VEDRA, Florida – August 18, 2022 –Cadrenal Therapeutics, Inc. (“Cadrenal”), a biopharmaceutical company focused on developing

Cadrenal Therapeutics Announces Appointment of Douglas Losordo, MD as Chief Medical Officer PONTE VEDRA, Florida – July 25, 2022 –Cadrenal Therapeutics, Inc. (“Cadrenal”), a biopharmaceutical

Cadrenal Therapeutics Announces Confidential Submission of Draft Registration Statement Related to Proposed Public Offering   PONTE VEDRA, Florida – July 15, 2022 – Cadrenal Therapeutics,

Cadrenal Therapeutics Appoints Matthew K. Szot as Chief Financial Officer  PONTE VEDRA, Florida – May 17, 2022 –Cadrenal Therapeutics, Inc. (“Cadrenal”), a biopharmaceutical company focused

Cadrenal Therapeutics Acquires Tecarfarin from Horizon PONTE VEDRA, Florida – April 1, 2022 – Cadrenal Therapeutics, Inc. (“Cadrenal”) has acquired the rights to tecarfarin from